Barclays
LENZ

Barclays’s LENZ Therapeutics LENZ Stock Holding History

Barclays’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
151,387
+78,955
+109% +$1.11M ﹤0.01% 2557
2025
Q4 		$1.16M Buy
72,432
+24,606
+51% +$717K ﹤0.01% 3329
2025
Q3 		$2.23M Buy
47,826
+2,016
+4% +$74.1K ﹤0.01% 2811
2025
Q2 		$1.34M Buy
45,810
+21,409
+88% +$582K ﹤0.01% 3135
2025
Q1 		$627K Sell
24,401
-5,656
-19% -$139K ﹤0.01% 3385
2024
Q4 		$868K Buy
30,057
+13,594
+83% +$414K ﹤0.01% 3466
2024
Q3 		$391K Buy
16,463
+12,051
+273% +$267K ﹤0.01% 3925
2024
Q2 		$76.3K Sell
4,412
-2,151
-33% -$37.6K ﹤0.01% 4035
2024
Q1 		$147K Sell
6,563
-5,216
-44% -$108K ﹤0.01% 4272
2023
Q4 		$216K Buy
11,779
+6,917
+142% +$114K ﹤0.01% 4381
2023
Q3 		$84.4K Buy
4,862
+4,057
+504% +$70.6K ﹤0.01% 3659
2023
Q2 		$14.7K Sell
805
-2,525
-76% -$50.5K ﹤0.01% 4178
2023
Q1 		$57.1K Buy
+3,330
New +$53.9K ﹤0.01% 4402
2022
Q2 		– Sell
-1,254
Closed -$44K – 5310
2022
Q1 		$44K Buy
+1,254
New +$78.4K ﹤0.01% 4166

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Barclays's LENZ Position: Q1 2026 in Review

Barclays increased its LENZ Therapeutics (LENZ) stake by 109% in Q1 2026, buying an estimated $1.11M and bringing the position to 151,387 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Barclays first reported a position in LENZ in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.23M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Barclays held 151,387 shares of LENZ Therapeutics worth $1.39M as of Q1 2026.
  • Barclays bought 78,955 LENZ Therapeutics shares in Q1 2026, an estimated $1.11M.
  • LENZ Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2557 holding.
  • Barclays first reported a position in LENZ Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Barclays's LENZ Therapeutics position peaked at $2.23M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.